Founded in 2009 and based in southern California, start-up [Epicardial Technologies Inc.] (ETI) is developing a potentially game-changing technology platform designed to enable physicians to more easily perform percutaneous, catheter-based ablation of common heart rhythm abnormalities, including atrial fibrillation (AF) and ventricular tachycardia (VT), from the inside or the outside (epicardial) surface of the heart, while protecting the structures surrounding the heart from serious damage or injury.
According to Kalyanam Shivkumar, MD, PhD, a founder and chief scientific advisor of Epicardial Technologies and also director of the Cardiac Arrhythmia Center at the University of California, Los...